Physician profile
Jigneshkumar Patel
NPI 1518088111
$10,321.47
in general payments reported to CMS, 2019-2025
31 companies · $4,599 in 2025
The $4,599 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $702 · 2021: $1,421 · 2022: $1,031 · 2023: $477 · 2024: $1,403 · 2025: $4,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,867 · Consulting Fee: $2,600 · Education: $12.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.78 |
| Consulting Fee | $2,600.00 |
| Education | $12.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,390.10 | 2019-2025 | |
| Mirum Pharmaceuticals, INC. | $2,707.66 | 2025 | Livmarli |
| Nestle Healthcare Nutrition INC. | $441.25 | 2020-2023 | |
| Intercept Pharmaceuticals, INC. | $411.46 | 2019-2025 | |
| Janssen Biotech, INC. | $403.62 | 2019-2025 | Tremfya |
| Medtronic, INC. | $398.74 | 2022-2025 | Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $327.08 | 2020-2025 | Entyvio, Eohilia |
| Pfizer INC. | $276.20 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $248.94 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $240.95 | 2021-2022 | |
| Ardelyx, INC. | $156.93 | 2024-2025 | Ibsrela |
| Allergan, INC. | $151.33 | 2019-2020 | |
| Celltrion USA INC. | $124.99 | 2025 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $124.12 | 2025 | |
| Celgene Corporation | $118.60 | 2021-2023 | Zeposia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $114.65 | 2025 | Axios |
| Lumendi LLC | $104.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $98.27 | 2021 | |
| Gilead Sciences, INC. | $78.99 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.77 | 2019-2021 | |
| Madrigal Pharmaceuticals | $62.91 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $51.83 | 2019-2020 | |
| Dova Pharmaceuticals | $45.18 | 2019 | |
| Genzyme Corporation | $31.38 | 2023 | |
| Redhill Biopharma INC. | $26.17 | 2022 | |
| Novo Nordisk INC | $24.88 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.09 | 2024 | Cyltezo |
| Aimmune Therapeutics, INC. | $20.19 | 2025 | Zenpep |
| Fresenius Kabi USA, LLC | $17.42 | 2024 | Idacio |
| Lucid Diagnostics INC. | $15.38 | 2023 | |
| Amgen INC. | $13.84 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jigneshkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.